Don’t Jump to Airsupra for Asthma Rescue

April 2024

Reps will tout albuterol/budesonide (Airsupra) as the first “dual-action” rescue inhaler FDA-approved for asthma in adults.

We’re used to reaching for albuterol for quick relief.

But this new short-acting beta-agonist/inhaled corticosteroid (ICS) combo aligns with guidelines moving toward anti-inflammatory reliever (AIR) options...instead of using albuterol alone.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Anxiety Weigh Med Options for Generalized Anxiety Disorder
Asthma Don’t Jump to Airsupra for Asthma Rescue
Acute Pain Help Treat Acute Pain in Patients on Chronic Opioids
Diabetes Tailor Glycemic Goals for Patients With Diabetes
COVID-19 Be Ready for Questions About Spring COVID-19 “Boosters”
Emergency Preparedness Prepare for the Next Cyberattack
HIV & AIDS Sort Through HIV Pre-Exposure Prophylaxis (PrEP) Options
NatMed Spotlight Tell Patients Not to Rely on Astaxanthin for Sun Protection

Don’t Jump to Airsupra for Asthma Rescue

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents